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Abstract
Purpose [11C]Lu AE92686 is a positron emission tomogra-
phy (PET) radioligand that has recently been validated for
examining phosphodiesterase 10A (PDE10A) in the human
striatum. [11C]Lu AE92686 has high affinity for PDE10A
(IC50 = 0.39 nM) and may also be suitable for examination
of the substantia nigra, a region with low density of
PDE10A. Here, we report characterization of regional
[11C]Lu AE92686 binding to PDE10A in the nonhuman pri-
mate (NHP) brain.
Methods A total of 11 PETmeasurements, seven baseline and
four following pretreatment with unlabeled Lu AE92686 or
the structurally unrelated PDE10A inhibitor MP-10, were per-
formed in five NHPs using a high resolution research
tomograph (HRRT). [11C]Lu AE92686 binding was
quantified using a radiometabolite-corrected arterial input
function and compartmental and graphical modeling
approaches.
Results Regional time-activity curves were best described
with the two-tissue compartment model (2TCM). However,
the distribution volume (VT) values for all regions were ob-
tained by the Logan plot analysis, as reliable cerebellar VT
values could not be derived by the 2TCM. For cerebellum, a
proposed reference region, VT values increased by ∼30%with
increasing PET measurement duration from 63 to 123 min,
while VT values in target regions remained stable. Both pre-
treatment drugs significantly decreased [11C]Lu AE92686
binding in target regions, while no significant effect on cere-
bellum was observed. Binding potential (BPND) values, de-
rived with the simplified reference tissuemodel (SRTM), were
13–17 in putamen and 3–5 in substantia nigra and correlated
well to values from the Logan plot analysis.
Conclusions The method proposed for quantification of
[11C]Lu AE92686 binding in applied studies in NHP is based
on 63min PET data and SRTMwith cerebellum as a reference
region. The study supports that [11C]Lu AE92686 can be used
for PET examinations of PDE10A binding also in substantia
nigra.
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Introduction
Phosphodiesterase 10A (PDE10A) is a member of the cyclic
nucleotide phosphodiesterase family and modulates intracel-
lular signal transduction by catabolizing cyclic adenosine
monophosphate (cAMP) and guanosine monophosphate
(cGMP) [1]. The intracellular enzyme PDE10A is almost
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exclusively expressed in GABAergic medium spiny neurons of
the striatum, where it is distributed to both cell bodies and pro-
cesses at presynaptic sites within globus pallidus (GP) and
substantia nigra (SN) [1–5]. The localization in the basal ganglia
and interaction with dopaminergic neurotransmission [5, 6] sug-
gest that PDE10A may play a role in striatal functions such as
cognitive and motor abilities [1, 6, 7]. PDE10A has, therefore,
been considered as a potential therapeutic target for several neu-
ropsychiatric disorders, including schizophrenia, bipolar disor-
der, Huntington’s disease and Parkinson’s disease [1, 7, 8].
Numerous potential radioligands for imaging of PDE10A
binding by positron emission tomography (PET) have been
suggested and several have been examined in nonhuman pri-
mates (NHP) or in humans [8–19]. Most of these radioligands
provide adequate target-to-background signal for the striatum
and GP, but so far, radioligand binding in the SN has been
examined only for [18F]JNJ-42259152 or [11C]IMA107. Both
studies report binding potential (BPND) values of approxi-
mately 0.5 for SN in healthy human subjects with correspond-
ing striatal BPND values of 3.5 or 2.2, respectively [8, 16].
This low BPND value might limit the application of these
radioligands for quantitative examinations of PDE10A bind-
ing in SN [20]. Considering that the SN is a key nucleus in
relation to the basal ganglia [21], and that regional differences
in PDE10A functioning may be a part of the pathophysiology
of neuropsychiatric disorders [2, 5, 6], it is important to de-
velop a PETmethodology enabling quantification of PDE10A
binding in the SN of the primate brain.
[11C]Lu AE92686 is a recently developed radioligand with
high affinity for PDE10A (IC50 = 0.39 nM). An evaluation of
the radioligand in humans has previously been reported [9]. The
characteristics of this radioligand are promising, with striatal
BPND value around 7.5 in humans [9], which is higher than
those reported for other PDE10A radioligands (typical range:
2–5) [8–19]. Preliminary examination of [11C]Lu AE92686 in
cynomolgus monkeys has suggested that [11C]Lu AE92686
binding is high in the striatum (BPND around 6.5), and the
specificity of binding was demonstrated by dose-dependent re-
duction in uptake of [11C]Lu AE92686 following the adminis-
tration of PDE10A inhibitor MP-10 [9]. However, the initial
study in monkeys did not include a full kinetic evaluation of
[11C]Lu AE92686 or examination of binding in the SN.
The aim of the present study was to further characterize the
binding properties of [11C]Lu AE92686 in NHPs. To enable
examinations of PDE10A binding in the SN, PET measure-
ments were conducted using the High Resolution Research
Tomograph (HRRT). For full kinetic quantification of
[11C]Lu AE92686 binding, a metabolite-corrected arterial in-
put function (AIF) was obtained. Moreover, pretreatment ex-
periments with unlabeled Lu AE92686 or the structurally un-
related PDE10A inhibitor MP-10 were performed to further
characterize the specificity of binding and to evaluate the suit-
ability of cerebellum as a reference region.
Materials and methods
Subjects
The study was approved by the Animal Research Ethical
Committee of the Northern Stockholm region (Dnr N452/11,
N632/12, N633/12 and N185/14). Five female cynomolgus
monkeys (Macaca fascicularis) with body weight: 6.4 ±
1.7 kg (mean±standard deviation (SD)), for all following
values with the same format) were included. The caring and
experimental procedures were performed according to the
‘Guidelines for planning, conducting and documenting exper-
imental research’ (Dnr 4820/06-600) of Karolinska Institutet
and the ‘Guide for the Care and Use of Laboratory Animals:
Eighth Edition’ [22].
Preparation of [11C]Lu AE92686
[11C]Lu AE92686 was prepared according to procedures re-
ported previously [9] as described in Online Resource 1.
Study design
A total of 11 PET measurements with arterial blood sampling
were performed on seven experimental days. Each monkey
underwent one baseline PET measurement on each experi-
mental day and on four experimental days a consecutive
PET measurement was conducted after pretreatment with
MP-10 (1.5 mg/kg, NHP1 and NHP2) or Lu AE92686
(0.5 mg/kg or 2.0 mg/kg, NHP1). The interval between the
two PET measurements on the same day was approximately
3 h.
Test drug administration
MP-10 [23] was formulated in a mixture of PEG 400 (25 %,
v/v) and 0.9 % saline (75 %, v/v), and Lu AE92686 was
formulated in a mixture of 10 % hydroxypropyl beta cyclo-
dextrin dissolved in phosphate buffered saline (PBS). All drug
solutions were infused (∼1 mL/kg) over 15 min, starting
45 min before injection of [11C]Lu AE92686.
PET experimental procedures
Anesthesia was initiated by intramuscular injection of keta-
mine hydrochloride (∼10 mg/kg) and maintained by
sevoflurane (2–8 %). PET measurements were conducted in
the HRRT; a six-minute transmission scan (using a single
Cesium-137 source) was followed by the acquisition of list-
mode data for 123 min after a bolus injection of [11C]Lu
AE92686.
Arterial blood samples were collected continuously during
the first 3 min after radioligand injection by using an
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automated blood sampling system, and subsequent arterial
blood samples were takenmanually.Manual samples included
one sample for determination of protein binding (5 min before
radioligand injection), 14 samples (at 0.5, 1.0, 1.5, 2.0, 2.5,
3.0, 4.0, 5.0, 8.0, 15, 30, 60, 90 and 120min) for measurement
of blood and plasma radioactivity and seven samples (at 2.5,
4.0, 15, 30, 60, 90 and 120 min) for radiometabolite analyses.
In the pretreatment experiments, five additional blood samples
(at 15, 30, 60, 90 and 120 min) were taken for determination
of plasma drug concentrations.
Blood samples analysis
The free fraction (fp) of [
11C]Lu AE92686 in plasma was
estimated by ultrafiltration, and the percentages of radioactiv-
ity for unchanged radioligand and radiometabolites in plasma
were determined by reversed-phase high-performance liquid
chromatography (HPLC) according to procedures reported
previously [14, 24]. Plasma drug concentrations were deter-
mined using ultra performance liquid chromatography
(UPLC) followed by tandem mass spectrometry (MS/MS)
detection according to procedures reported previously [25].
The details of the blood sample analysis are described in
Online Resource 1.
Image data analysis
Each monkey underwent magnetic resonance imaging
(MRI), and the images were used for anatomical guidance
to define regional volumes of interest (VOIs). PET images
were preprocessed according to previously reported
methods [26] with reconstructed image frames binned as:
9 × 20 s, 3 × 60 s, 5 × 180 s and 17 × 360 s. Each subject’s
baseline blood flow by dominated PET image (average of
time frames corresponding to 0–9 min) was coregistered
manually to their individual MRI image, and the resulting
transformation matrices were applied to the corresponding
dynamic PET image. For pretreatment studies, the transfor-
mation parameters of the baseline measurements were ap-
plied to both of the two PET measurements performed on
the same day.
Six VOIs were defined, including three striatal regions:
putamen, caudate nucleus (CN) and ventral striatum (VS),
two extrastriatal regions: GP and SN and one reference region:
cerebellum. A decay-corrected time–activity curve (TAC) was
generated for each VOI from the coregistrated dynamic PET
data and radioactivity was expressed as standardized uptake
values (SUV), which were calculated from the radioactivity
concentration as [kBq/cm3] / (radioactivity injected [MBq] /
body weight [kg]). Specific binding was defined as radioac-
tivity in target region minus radioactivity in cerebellum.
Quantification of PET signals
Kinetic analysis was performed by applying the 1-tissue
compartment model (1TCM) and the 2-tissue compartment
model (2TCM). Logan plot analysis [27] was also applied
and the starting time of linearization (t*) was decided for
each VOI in each experiment separately by examining total
distribution volume (VT) and identifiability of VT based on
different t* ranging from 6 min to a time point with five
time frames remaining until the end of PET measurement.
In addition to the acquisition of 123 min data, the effects of
the PET measurement duration on VT estimates were exam-
ined by varying the time interval from 0 to 33 min to 0–
117 min with one time frame increments. BPND was derived
by three approaches, the indirect method using the follow-
ing equation
BPND ¼ Regional VT−Cerebellar VTCerebellar VT ; ð1Þ
and two reference tissue models: the simplified reference
tissue model (SRTM) [28] and Logan reference tissue mod-
el (Loganref) [29]. The efflux rate constant k2′ in Loganref
was derived by using SRTM and couple fitting of all target
regions except SN (excluded due to its relatively high noise
levels). The t* for Loganref was 27 min, based on the re-
sults of the Logan plot analysis.
All analyses of imaging data were performed using
PMOD (version 3.403; PMOD Technologies, Zurich,
Switzerland). The fits obtained by different models were
evaluated by the model selection criterion (MSC) [30],
for which a higher value indicates a better fit. The
identifiability of parameters was expressed by the per-
centage of the coefficient of variation (%COV) calculat-
ed according to the following equation
%COV ¼ Standard error of estimates=Estimates of parametersð Þ  100: ð2Þ
Poor identifiability was defined as %COV > 10 %. For
the pretreatment studies, Lassen plots [31] were applied
to estimate the nondisplaceable distribution volume
(VND) and PDE10A occupancy. Due to the significant
difference of the plasma free fraction (fp) before and after
pretreatment (see results section), the evaluation of pre-
treatment effect was based on VT or VND values normal-
ized for fp as VT/fp or VND/fp, respectively.
Results
All PETmeasurements were performed according to the study
protocol and no significant adverse effects were observed dur-
ing the pretreatment experiments.
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Radiochemistry
The radiochemical purity of [11C]Lu AE92686 was higher
than 99 %, and the average specific radioactivity at time of
injection was 1062 GBq/μmol (range: 609–1457 GBq/μmol),
corresponding to a mean injected mass of 0.07 μg (range:
0.04–0.12 μg).
Plasma radioactivity and radiometabolite analysis
[11C]Lu AE92686 was rapidly metabolized and parent com-
pound fraction was 18 ± 4 % of the plasma radioactivity at
60 min after injection (Fig. 1a). At 15 min after injection, three
main radiometabolite fractions ([11C]M1 – [11C]M3) eluted ear-
lier than [11C]Lu AE92686 (Fig 1b). At later time points,
[11C]M1 and [11C]M2 could not be separated and the combined
fraction increased with time until 90 min post injection (Fig. 1a).
In addition, several small radiometabolite fractions ([11C]M4)
eluted later than [11C]Lu AE92686 (Fig. 1c). The time course
of plasma radioactivity of parent [11C]Lu AE92686 at baseline
measurements (n = 7) is presented in Fig. 1d.
Quantification of [11C]Lu AE92686 receptor binding
After intravenous injection of [11C]Lu AE92686 at baseline
conditions, there was a rapid increase of radioactivity in re-
gions known to express PDE10A (Fig. 2, left column). The
TACs for target regions and cerebellum are shown in Fig. 3a.
Specific binding, when defined as the difference between ra-
dioactivity in target region and the cerebellum, reached max-
imum values within 60min after injection for all target regions
(Fig. 3b).
The regional TACs were first interpreted by the 1TCM and
2TCM. For target regions, both models appeared to describe
experimental data equally well. For cerebellum, the 2TCM
described TACs better than the 1TCM (Fig. 4a). A summary
of model parameters is given in Table 1. There were statisti-
cally higher MSC values for the 2TCM than for 1TCM in SN
(P < 0.01) and in cerebellum (P < 0.0001) as well as when
Fig. 1 Composition of radioactivity in arterial plasma samples after
[11C]Lu AE92686 injection in baseline experiments. (a) Plasma
composition of unchanged radioligand (mean±SD) and radiometabolites
(mean) fractions over time (n = 7) (b) Representative HPLC
radiochromatogram of plasma content 15 min post injection (c) HPLC:
60 min post injection (d) Radiometabolite-corrected arterial input
function of [11C]Lu AE92686 (n = 7) from 0 to 3 min (mean±SD); inset
shows values from 3 to 120 min (mean – SD), expressed in standardized
uptake value (SUV)
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pooling all six regions (2.8 ± 1.3 and 3.1 ± 1.3, P < 0.0001).
For the 2TCM, mean K1 values ranged from 0.06 to 0.11 with
mean %COV from 3 to 17 %. The estimated k3, k4, K1/k2 and
k3/k4 values suffered from poor identifiability (%COV> 50 %
in most fits). Furthermore, the 2TCM had poor VT
identifiability (%COV > 10 %) in all fits for the cerebellum
and in a few fits for the target regions (four of 35 fits).
Data were also interpreted by Logan plot analysis with AIF
(Fig. 4b), and identifiable VT estimates (%COV ≤ 10 %) could
be derived for all regions and all subjects. VT values by Logan
plot analysis correlated with those obtained by the 2TCMwith
%COV ≤ 10 % (Pearson r > 0.99, P < 0.0001, n = 30).
However, the values were slightly lower than those obtained
using 2TCM (−6.3 ± 2.6 %). When comparing the two
Fig. 2 Magnetic resonance
images and corresponding
coregistrated PET summation
images (average of frames from 9
to 123 min) of [11C]Lu AE92686
during baseline (mean of three
baseline experiments) and three
pretreatment conditions in NHP1.
(a) Axial (top) and coronal
(bottom) view of images at the
level of striatum (b) Axial (top)
and coronal (bottom) view of
images at the level of substantia
nigra; note the difference in the
range of the standardized uptake
value (SUV) colour bars between
(a) and (b)
Fig. 3 Time-activity course of radioactivity in brain for baseline
experiments (n = 7), expressed in standardized uptake value (SUV). (a)
Mean regional brain radioactivity concentrations in five target regions:
putamen (PUT), caudate nucleus (CN), globus pallidum (GP), ventral
striatum (VS), and substantia nigra (SN) as well as one reference region:
cerebellum (CB) (b) Mean regional specific binding (radioactivity in
target region - radioactivity in cerebellum) in five target regions
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models, the equation for the linear regression analysis was y =
0.934x + 0.015 (R2 > 0.99). In the following, the analyses
were based on the VT values obtained by Logan plot analysis,
since this model provided well identifiable values for all re-
gions, including cerebellum.
In target regions and PET data set of less than 63 min,
VT estimates were unstable (high variation with different
t*) and poorly identifiable VT estimates were obtained for
several regions (13 of 35 fits for 33 min data). The VT
values for the cerebellum increased prominently with
longer PET measurement duration as VT values for
33 min, 93 min and 123 min data accounted for 78.9 ±
3.4 %, 131.8 ± 16.6 % and 131.8 ± 10.4 % of the VT ob-
tained for 63 min data, respectively (Fig. 5a and b). The VT
values of target regions remained stable after increasing
PET measurement duration, and VT values for 123 min
data accounted for 101.3 ± 9.3 % of the VT obtained for
63 min data (Fig. 5b). To minimize the possible influence
of radiometabolites (see discussion section), 63 min was
chosen as the preferred PET measurement duration.
Fig. 4 Representative kinetic
modelling evaluation of [11C]Lu
AE92686 in one NHP. (a) One-
tissue compartment model
(1TCM) fits and two-tissue
compartment model (2TCM) fits
in the caudate nucleus (as in
putamen and globus pallidus),
substantia nigra (as in ventral
striatum), and cerebellum (b)
Corresponding Logan plot
analysis described the data
adequately for all regions
Table 1 Parameters estimated by the 1-tissue compartment model (1TCM) and the 2-tissue compartment model (2TCM) in baseline PET measure-
ments (n = 7)
1TCM 2TCM
VT (ml · cm





%COV %COV %COV %COV %COV
PUT 11.9 ± 3.8 4.2 ± 0.7 11.8 ± 3.7 4.3 ± 0.5 0.11 ± 0.02 0.55 ± 0.36 0.158 ± 0.105
2 ± 1 2 ± 1 6 ± 5 61 ± 43 79 ± 67b
CN 7.5 ± 2.4 3.8 ± 0.9 7.4 ± 2.4 4.0 ± 0.6 0.10 ± 0.02 0.34 ± 0.21d 0.137 ± 0.094d
2 ± 1 4 ± 6 4 ± 2 69 ± 52d 48 ± 47d
GP 10.3 ± 3.1 2.9 ± 0.7 10.3 ± 3.1 3.0 ± 0.5 0.08 ± 0.02 0.49 ± 0.48 0.058 ± 0.024b
4 ± 1 5 ± 2 17 ± 13 124 ± 8 113 ± 34b
VS 3.8 ± 1.2 2.2 ± 0.4 4.0 ± 1.3b 2.3 ± 0.2 0.10 ± 0.03 0.44 ± 0.63 0.080 ± 0.036b
3 ± 1 4 ± 2b 9 ± 6 124 ± 128 63 ± 35b
SN 2.7 ± 0.9 0.8 ± 0.6 2.6 ± 0.7b 1.1 ± 0.5* 0.06 ± 0.01b 0.26 ± 0.33 0.038 ± 0.009b
7 ± 3 7 ± 2b 11 ± 4b 82 ± 29 38 ± 23b
CB 0.2 ± 0.1 2.8 ± 0.5 0.9 ± 0.4e 4.2 ± 0.6* 0.09 ± 0.02 0.02 ± 0.01 0.003 ± 0.004c
6 ± 2 28 ± 16e 3 ± 1 23 ± 6 144 ± 130c
Data presented as mean±SD
VT total distribution volume,COV the coefficient of variation,MSCmodel selection criterion, PUT Putamen,CNCaudate nucleus,GPGlobus pallidum,
VS Ventral striatum, SN Substantia nigra, CB Cerebellum
a unit = ml · min−1 · cm−3
b n = 6; c n = 5; d n = 4; e n = 3 (excluding data with %COV > 50 % for VT or K1 and data with %COV> 500 % for k3 or k4)
*P < 0.05 (two tailed, comparing the results for 1TCM and 2TCM by paired t-test)
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Pretreatment experiments
Five blood samples were obtained within the period of the
PET measurements for assessment of the plasma concentra-
tion of the pretreatment drugs. The mean plasma concentra-
tions were 685 and 749 ng/mL after injection of MP-10,
109 ng/mL after injection of Lu AE92686 0.5 mg/kg and
388 ng/mL after Lu AE92686 2.0 mg/kg. (Fig. S1 in Online
Resource 2). The metabolic rate of [11C]Lu AE92686 after
pretreatment was similar to baseline conditions (Fig. S2 in
Online Resource 2).
Following administration ofMP-10 or Lu AE92686, radio-
activity was lower in all target regions when compared to
baseline (Fig. 6a–c). Radioactivity concentrations in the cere-
bellum were similar between baseline and pretreatment con-
ditions (Fig. 6d). The pooledK1 values obtained by the 2TCM
were 0.092 ± 0.029 at baseline conditions and 0.221 ± 0.114
(P < 0.0001) after pretreatment, suggesting a drug effect on
blood flow.
The plasma free fraction (fp) of [
11C]Lu AE92686 was
0.06 ± 0.01 during baseline conditions, whereas it was higher
after administration of MP-10 (0.14 and 0.09) or Lu AE92686
(0.07 and 0.15 for 0.5 mg/kg and 2.0 mg/kg, respectively).
Both MP-10 and Lu AE92686 induced a significant reduction
in VT/fp in target regions, and the reduction in VT/fp was larger
after the higher dose of Lu AE92686 (Table 2). For the cere-
bellum, there was no statistical significant difference (4.8 ±
15.4 %, P = 0.55) in VT/fp between baseline (8.6 ± 2.5) and
pretreatment (9.0 ± 2.5) conditions (Table 2).
The PDE10A occupancy after pretreatment was estimated
using Lassen plots (Fig. 7). In all studies the goodness of fit
(R2) for linear fitting was higher than 0.90. In the two NHPs
receiving MP-10, the estimated PDE10A occupancy was
93 % and 95 % (Fig. 7a and b). The estimated PDE10A oc-
cupancy by Lu AE92686 was 84 % and 96 % after 0.5 mg/kg
and 2.0 mg/kg, respectively (Fig. 7c and d). For these four
pretreatment experiments, there was a trend towards VND/fp
values (8.6 ± 2.5) being lower than VT/fp values for the cere-
bellum at baseline conditions (15.2 ± 5.7) (P = 0.08).
Reference tissue models
The cerebellum was used as a reference region, since there
was no significant reduction of binding after pretreatment.
The baseline VT values of target regions and cerebellum are
given in Table 3. BPND values could be derived in all exper-
iments by using SRTM or Loganref (Fig. 8a and b). The base-
line BPND values calculated by the different models are pre-
sented in Table 3. Since the results of the two reference tissue
models were comparable (absolute difference: 5.0 ± 4.4 %,
Pearson r > 0.99 and P < 0.0001), only the results of the
SRTM are reported in the following sections.
The BPND values calculated by SRTM in the baseline mea-
surements were lower than those derived indirectly by Logan
plot analysis (−19.7 ± 18.2 %, median: −23.3 %) and the dif-
ference became mildly positive in pretreatment experiments
(5.8 ± 16.8 %, median: 1.5 %) (Fig. 8c). The negative differ-
ence (%) became larger at higher BPND values both for base-
line measurements (Pearson r = −0.88 and P < 0.0001) and
pretreatment measurements (Pearson r = −0.50 and P =
0.03). There was a significant correlation between BPND
values calculated by Logan plot analysis and SRTM in the
baseline measurements (Pearson r = 0.95, P < 0.0001) and in
the pretreatment measurements (Pearson r = 0.98,
P < 0.0001). When pooling baseline and pretreatment data,
the equation for the linear regression analysis was y =
0.601x + 1.295 (R2 = 0.95) (Fig. 8d).
Discussion
In the current study, we conducted kinetic analyses of [11C]Lu
AE92686 to evaluate the suitability of this radioligand for
PET examinations of regional PDE10A binding in the mon-
key brain. There are three main observations: first, regional
[11C]Lu AE92686 binding could be quantified in the striatum,
GP and SN using Logan plot analysis as well as reference
tissue models. Second, pretreatment studies confirmed the
specificity of [11C]Lu AE92686 binding to PDE10A, and
there was no evident effect of pretreatment on PDE10A bind-
ing in the cerebellum. Third, an influence of blood–brain bar-
rier (BBB) penetrating radiometabolites on brain radioactivity
could not be excluded and was minimized by using PET data
only for the first 63 min after injection. In conclusion, [11C]Lu
AE92686 has potential for examinations of PDE10A binding
not only in the striatum and GP but also in the SN in future
NHP PET studies.
Kinetic analyses of [11C]Lu AE92686 suggested that both
the 1TCM and 2TCM could describe the TACs for regions
with high PDE10A binding. However, the TACs were best
described with the 2TCM in regions with low or no specific
binding such as SN or cerebellum. The results for the striatum
and cerebellum are compatible with a previous evaluation of
[11C]Lu AE92686 in humans, though the TACs for the human
cerebellum were best described by the irreversible 2TCM in
the previous study [9], we found no significant difference in
MSC values between reversible and irreversible 2TCM. A
possible explanation is that some small compartments may
represent a larger part of the total signal in regions with low
or no specific binding and, thus, are identified by the model.
Overall, the radioactivity in the cerebellumwas about 10%
of radioactivity in the putamen (Fig. 3a). The low signal for
the cerebellum could be a reason for poor identifiability of VT
values in this region when using 2TCM [9]. In contrast, Logan
plot analysis provided less variable VT values in all regions
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with a %COV< 10 %. Therefore, the Logan plot analysis is
the recommended quantification method for estimating VT
values by [11C]Lu AE92686 in NHPs and in humans [9].
In agreement with a previous report in humans [9], there
were no major differences between the two examined refer-
ence tissue models, SRTM and Loganref, used to quantify
regional [11C]Lu AE92686 binding. When considering the
reference tissue model performance criteria recently proposed
by Zanderigo and coworkers [32], it can be noted that the
correlation between pooled BPND values of reference tissue
models and Logan plot analysis was high (>0.95, proposed:
>0.5) and the median percent difference of BPND values be-
tween reference tissue models and Logan plot analysis was
low (1.5 % to 23.3 %, proposed: <50 %). Fulfillment of these
two criteria suggests that SRTM and Loganref may be used to
quantify [11C]Lu AE92686 binding with acceptable accuracy.
In addition to the two criteria mentioned above, the third
proposed performance criterion is a slope of the linear regres-
sion line of BPND values between reference tissue models and
AIF-based quantification method within the range of 0.7–1.3
(corresponding to a maximum relative difference ≤ 30 %)
[32]. In the current study, the slope was 0.6 suggesting that
the maximum relative difference in reference tissue models
was higher than the proposed level. The deviation between
the regression line and the line of identity is mainly driven
by regions with high PDE10A density (Fig. 8c and d). Since
Fig. 6 Time-activity course for
radioactivity in brain for baseline




AE92686 in one NHP, expressed
in standardized uptake value
(SUV). Regional brain
radioactivity concentrations in (a)
caudate nucleus, (b) globus
pallidus, (c) substantia nigra and
(d) cerebellum
Fig. 5 Effect of PET measurement duration on VT values derived by the
Logan plot analysis; Relative VT values (%) = [(VT values by
corresponding duration of PET measurement - VT values by reference
duration of PET measurement) / VT values by reference duration of
PET measurement] × 100 (a) Cerebellar VT values (mean±SD) (b)
Relative VT values to 63 min data for target regions (mean – SD) and
cerebellum (mean+SD)
Eur J Nucl Med Mol Imaging (2017) 44:308–320 315
the current BPND values in target regions are relatively high
(>15), a relatively large maximum difference in BPND esti-
mates by SRTM can be anticipated. Similar observations have
previously been reported for several other radioligands, in-
cluding [11C]Cimbi-36, [11C]WAY-100635 and [11C]FLB
457 [24, 33–35]. As for these established radioligands, refer-
ence tissue models may be considered for quantification of
[11C]Lu AE92686 binding in NHP studies in particular when
multiple PET measurements are performed on the same sub-
ject such as in pharmacological challenge studies [32, 34, 36].
The pretreatment studies in the current study extend report-
ed work, which has been performed in NHP without AIF [9].
The high reduction of [11C]Lu AE92686 binding in target
regions after pretreatment with MP-10, a PDE10A inhibitor
from a different structural class than Lu AE92686, supports
the view that [11C]Lu AE92686 binds specifically to
PDE10A. In all pretreatment studies, the fit of the Lassen plots
was good (R2 from 0.93 to >0.99). These results suggest that
the regional PDE10A occupancy was homogenous and that
all five target regions have a similar VND [31].
In addition, pretreatment byMP-10 or Lu AE92686 did not
significantly reduce the cerebellar VT/fp values. The
Fig. 7 Lassen plots using VT/fp values obtained during baseline
conditions and after MP-10 or unlabeled Lu AE92686 pretreatment
before injection of [11C]Lu AE92686; the regression analysis included
five target regions: putamen (PUT), caudate nucleus (CN), globus
pallidum (GP), ventral striatum (VS) and substantia nigra (SN) while
cerebellum (open circle) was not included in the regression model. (a)
MP-10 1.5 mg/kg in NHP2 (b) MP-10 1.5 mg/kg in NHP1 (c) Lu
AE92686 0.5 mg/kg (d) Lu AE92686 2.0 mg/kg
Table 2 Changes in regional VT / fp (%)










PUT −89.2 −87.9 −80.5 −93.7
CN −88.0 −86.3 −76.4 −92.8
GP −76.4 −76.2 −54.9 −90.3
VS −81.6 −77.2 −66.2 −89.8
SN −46.7 −43.2 −23.4 −75.8
CB 1.0 −3.5 26.3 −9.7
PUT Putamen, CN Caudate nucleus, GP Globus pallidum, VS Ventral
striatum, SN Substantia nigra, CB Cerebellum
aChange in VT / fp (%) = (PretreatmentBaselineBaseline Þ  100
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discrepancies between estimated VND/fp values and baseline
cerebellum VT/fp values were possibly attributed to the noise
in baseline VT/fp values. Such noise violates the assumption of
noiseless data in the x-axis of the standard linear regression
model in the Lassen plots used for calculation of occupancy
[37]. Overall, these results support the use of cerebellum as a
reference region in the quantification of [11C]Lu AE92686
binding.
The TACs of the cerebellum were better described by the
2TCM than the 1TCM, similarly as has been described for
several other PDE10A radioligands [10, 11, 14, 16, 18].
Possible explanations for this include a small fraction of spe-
cific binding, a kinetically distinguishable nondisplaceable
compartment, tissue heterogeneity (gray and white matter),
or a contamination from BBB-penetrating radiometabolites
[38, 39]. A presence of BBB-penetrating radiometabolites
was supported by the continuous increase in cerebellar VT
values with increasing PET measurement duration [40]. In
contrast, VT values in target regions remained stable with in-
creasing PET measurement duration from 63 to 123 min.
Fig. 8 Representative results of
simplified reference tissue model
(SRTM) and Logan reference
tissue model (Loganref) for
63 min data of [11C]Lu AE92686
in one NHP (reference region:
cerebellum). (a) SRTM fits in
caudate nucleus (CN) and
substantia nigra (SN) for baseline
and Lu AE92686 2.0 mg/kg
pretreatment condition (b)
Loganref fits in CN and SN for
baseline and Lu AE92686
2.0 mg/kg pretreatment condition
(c) Bland-Altman plot; Difference
of BPND (%) = [(SRTM - Logan
plot analysis) / Logan plot
analysis] × 100 (d) Linear
regression analysis; dotted lines
represent the line of identity
Table 3 VT values for all
baseline experiments (n = 7) by
Logan plot analysis and
comparisons to baseline BPND
values estimated by different
reference tissue models
VT %COV BPND % COV
Logan plots Logan plots Logan plots SRTM Loganref SRTM
PUT 12.3 ± 4.5 3.8 ± 2.2 24.3 ± 6.7 15.0 ± 2.1 15.0 ± 2.3 2.2 ± 0.3
CN 7.2 ± 2.5 3.3 ± 2.6 13.8 ± 3.1 10.4 ± 1.3 10.0 ± 1.2 2.1 ± 0.4
GP 8.8 ± 2.5 7.9 ± 1.4 17.2 ± 3.4 11.2 ± 1.4 11.1 ± 1.4 3.6 ± 1.1
VS 3.6 ± 1.2 3.8 ± 2.6 6.5 ± 1.7 6.1 ± 1.1 5.7 ± 1.1 4.3 ± 1.2
SN 2.3 ± 0.5 7.7 ± 2.6 3.8 ± 0.8 3.7 ± 0.4 3.4 ± 0.5 8.9 ± 2.0
CB 0.5 ± 0.1 8.8 ± 1.0 NA NA NA NA
Data presented as mean ± SD
COV the coefficient of variation, PUT Putamen, CN Caudate nucleus, GP Globus pallidum, VS Ventral striatum,
SN Substantia nigra, CB Cerebellum, SRTM simplified reference tissue model, Loganref Logan reference tissue
model, NA not applicable
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Therefore, the potential BBB-penetrating radiometabolites
mainly influenced the quantification of radioactivity for the
cerebellum.
To minimize the poten t ia l con t r ibu t ion f rom
radiometabolites, it is preferred to apply the shortest PETmea-
surement duration, which is sufficient for reliable estimation
of VT values by Logan plot analysis. Using 63 min PET data,
reliable VT values could be derived by Logan plot analysis
both in target regions and cerebellum. PET measurement du-
ration shorter than 63 min resulted in variable and poor iden-
tifiable VT estimates in several regions. Furthermore, it should
be considered that due to the rapid decay of 11C (half-life =
20min), a longer measurement duration might introduce more
noise both in the image and blood data. Shortening of the PET
measurement duration has also been proposed for the applica-
tion of other PDE10A radioligand, e.g. [18F]JNJ-42259152 in
rats, to overcome the confounding effects from BBB-
penetrating radiometabolites [17]. Therefore, 63 min is sug-
gested as the preferred PETmeasurement duration for [11C]Lu
AE92686 binding in cynomolgus monkeys.
The metabolic rate of [11C]Lu AE92686 in monkeys is
similar to rats, but more rapid than previously reported in
humans [9]. It is worth noting that we compared the fraction
of unchanged [11C]Lu AE92686 to the total amount of radio-
activity in plasma across species. This relative fraction of
unchanged [11C]Lu AE92686 in plasma is dependent on the
clearance rate of the radiometabolites in plasma, a rate which
also may differ across species. However, in general, the po-
tential difference in metabolic rate across species is consistent
with less extensive metabolism in higher species, an observa-
tion previously reported for other radioligands [10, 11, 16, 17,
41].
The radiometabolites observed early in monkey plasma
were more hydrophilic than [11C]Lu AE92686, similar as in
rat and human [9]. These observations are consistent with the
results of a metabolic soft-spot mass spectrometry analysis of
Lu AE92686. After incubation in rat and human liver micro-
somes, only hydroxy and di-hydroxy metabolites were sug-
gested, and all metabolites were more hydrophilic than the
parent compound (unpublished data, data on file at
Lundbeck). It has been reported that at 40 min post-injection,
the amount of radiometabolites in rat brain is small (<15 %)
[9]. It may thus be anticipated that the majority of radioactivity
in the NHP brain at 60 min post-injection would be [11C]Lu
AE92686. Ideally, the structure of the metabolites would be
identified and, if possible, the metabolites radiolabeled to ex-
amine their passage across the BBB. Further studies are war-
ranted to characterize these radiometabolites and to further
confirm their influence on the quantification of [11C]Lu
AE92686 in the NHP brain.
Table 4 Summary of PDE10A PET radioligands evaluated in primatesa
Radioligand Species PreTx Duration effectc Reference region PUT SN TRT (%) Ref
[11C]Lu AE92686 Human (n = 6) NA NA CB 7.5d NA 6 9
Cynomolgus (n = 2) Ab NA CB 6.5d NA NA 9
Cynomolgus (n = 5) A Ab CB 15.0 3.7 NA *
[11C]MP-10 Baboon (n = 4) A NA CB 1.6 NA NA 10
Rhesus (n = 4) A NA NA NA NA NA 11
[11C]IMA107 Baboon (n = 2) A NA CB 4.3 0.5e NA 08/12
[11C]AMG 7980 Baboon (n = 2) A NA Thalamus 0.8 NA NA 13
[11C]T-773 Rhesus (n = 2) A NA CB 2.2 NA NA 14
[11C]TZ1964B Cynomolgus (n = 2) Ab NA CB 4.6d NA NA 15
[18F]JNJ-42259152 Human (n = 12) NA A Frontal ctx 3.5 0.4 5–12 16
[18F]MNI-659 Human (n = 5) NA A CB 3.8 NA 5–8 18
[18F]AMG 580 Rhesus (n = 1) NA NA Midbrain 2.9 NA NA 19
Baboon (n = 2) NA NA Thalamus NA NA NA 19
PreTx pretreatment experiment with PDE10A inhibitor or unlabelled radioligand, NA not applicable, A available, CB Cerebellum, Frontal ctx Frontal





   100
a Based on the literature describing the quantification or characterization of the radioligands
bNo arterial input function
c Effect of PET measurement duration on quantification
dBPND values in striatum
eReported in a human study (n = 12, healthy subjects)
*Current study
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A large number of PET radioligands have been developed
for the PDE10A enzyme [8–19]. Table 4 summarizes the char-
acteristics of PDE10A radioligands that have been applied in
primates. After adjustment for the differences in target VOI
(putamen vs. striatum) and PET measurement duration
(63 min vs. 90 min), the striatal BPND values (12.0 ± 1.6) in
the current study were 85 % higher than previously reported
values with [11C]Lu AE92686 in cynomolgus monkeys [9].
This difference may be caused by an enhanced striatum signal
in the current study due to the resolution of the PET systems
(1.6 mm vs. 3.5 mm) and to the use of a head fixation device,
limiting head motion in the current study. Similar differences
between PET systems have been reported in imaging studies
of dopamine or serotonin transporters, with an increase in
BPND values of up to 92 % when using the HRRT [42, 43].
It is noted that the majority of the studies of PDE10A
radioligands did not in detail evaluate the influence of
radiometabolites on quantification. For example, only studies
using [18F]JNJ-42259152 [16] or [18F]MNI-659 [18] have
examined the effect of PET measurement duration on the
quantification, and for both radioligands an increase in VT
value was obtained with increasing PET measurement
duration.
[11C]Lu AE92686 binding in SN could be quantified with
favorable signal to noise ratio. The BPND for SN was 3–5,
which is higher than ∼0.5 as reported in studies using other
PDE10A radioligands and lower resolution PET systems [8,
16] (Table 4). A head-to-head comparison on the HRRT is
required to allow for a direct comparison of SN binding by
different PDE10A radioligands. In general, considering the
relative small size of SN (56 ± 14 mm3 in the current study),
BPND values higher than 0.5 have been suggested to be re-
quired for reliable quantification [20]. The pretreatment stud-
ies in the current study confirm that the nondisplaceable bind-
ing in the SN is similar to that in the striatum. In conclusion,
[11C]Lu AE92686 may allow for the unique potential to quan-
tify PDE10A binding in the SN. Such studies in nonhuman
primates and humansmay lead to a better understanding of the
role of PDE10A in the pathophysiology and treatment of neu-
ropsychiatric diseases.
A limitation of the current study is the use of anesthesia
during PET measurements. The induction by ketamine and
maintenance by sevoflurane is similar to the previously report-
ed monkey study with [11C]Lu AE92686 [9]. The influence of
these anesthetics on the expression of PDE10A or cAMP con-
centration is to our knowledge not known. However, the
striatal binding of [11C]Lu AE92686 in awake humans and
anaesthetized monkeys has been reported to be comparable
in a previous study [9]. Therefore, the anesthesia effects on
the binding of [11C]Lu AE92686 are unlikely to be prominent.
In conclusion, our results suggest that [11C]Lu AE92686
can be applied to examine PDE10A binding in striatum, GP
and SN. A potential contribution from radiometabolites can be
minimized by shortening the PET measurement duration to
63 min. Reliable BPND estimates could be derived by refer-
ence tissue models (SRTM and Loganref) and these models
are the preferred methods in future pharmacological challenge
studies in NHPs.
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